tetano
Editor, Senior Moderator
Front Immunol
. 2023 Mar 8;14:1112505.
doi: 10.3389/fimmu.2023.1112505. eCollection 2023.
Novel ACE2 fusion protein with adapting activity against SARS-CoV-2 variants in vitro
Latifa Zekri[SUP] 1 2 3 4 [/SUP], Natalia Ruetalo[SUP] 5 [/SUP], Mary Christie[SUP] 6 [/SUP], Carolin Walker[SUP] 1 2 [/SUP], Timo Manz[SUP] 1 2 [/SUP], Hans-Georg Rammensee[SUP] 1 2 4 [/SUP], Helmut R Salih[SUP] 2 3 4 [/SUP], Michael Schindler[SUP] 5 [/SUP], Gundram Jung[SUP] 1 2 4 [/SUP]
Affiliations
Abstract
Despite the successful development of vaccines and neutralizing antibodies to limit the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerging variants prolong the pandemic and emphasize the persistent need to develop effective antiviral treatment regimens. Recombinant antibodies directed to the original SARS-CoV-2 have been successfully used to treat established viral disease. However, emerging viral variants escape the recognition by those antibodies. Here we report the engineering of an optimized ACE2 fusion protein, designated ACE2-M, which comprises a human IgG1 Fc domain with abrogated Fc-receptor binding linked to a catalytically-inactive ACE2 extracellular domain that displays increased apparent affinity to the B.1 spike protein. The affinity and neutralization capacity of ACE2-M is unaffected or even enhanced by mutations present in the spike protein of viral variants. In contrast, a recombinant neutralizing reference antibody, as well as antibodies present in the sera of vaccinated individuals, lose activity against such variants. With its potential to resist viral immune escape ACE2-M appears to be particularly valuable in the context of pandemic preparedness towards newly emerging coronaviruses.
Keywords: ACE-2; SARS-CoV-2 therapy; fusion protein; immune escape; neutralizing antibodies.
. 2023 Mar 8;14:1112505.
doi: 10.3389/fimmu.2023.1112505. eCollection 2023.
Novel ACE2 fusion protein with adapting activity against SARS-CoV-2 variants in vitro
Latifa Zekri[SUP] 1 2 3 4 [/SUP], Natalia Ruetalo[SUP] 5 [/SUP], Mary Christie[SUP] 6 [/SUP], Carolin Walker[SUP] 1 2 [/SUP], Timo Manz[SUP] 1 2 [/SUP], Hans-Georg Rammensee[SUP] 1 2 4 [/SUP], Helmut R Salih[SUP] 2 3 4 [/SUP], Michael Schindler[SUP] 5 [/SUP], Gundram Jung[SUP] 1 2 4 [/SUP]
Affiliations
- PMID: 36969164
- PMCID: PMC10030959
- DOI: 10.3389/fimmu.2023.1112505
Abstract
Despite the successful development of vaccines and neutralizing antibodies to limit the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerging variants prolong the pandemic and emphasize the persistent need to develop effective antiviral treatment regimens. Recombinant antibodies directed to the original SARS-CoV-2 have been successfully used to treat established viral disease. However, emerging viral variants escape the recognition by those antibodies. Here we report the engineering of an optimized ACE2 fusion protein, designated ACE2-M, which comprises a human IgG1 Fc domain with abrogated Fc-receptor binding linked to a catalytically-inactive ACE2 extracellular domain that displays increased apparent affinity to the B.1 spike protein. The affinity and neutralization capacity of ACE2-M is unaffected or even enhanced by mutations present in the spike protein of viral variants. In contrast, a recombinant neutralizing reference antibody, as well as antibodies present in the sera of vaccinated individuals, lose activity against such variants. With its potential to resist viral immune escape ACE2-M appears to be particularly valuable in the context of pandemic preparedness towards newly emerging coronaviruses.
Keywords: ACE-2; SARS-CoV-2 therapy; fusion protein; immune escape; neutralizing antibodies.